FLT1 and neoplasm: Strong expression of VEGFR-1, -2 and PDGFR-β in tumor and endothelial cells (Fig. 1) may thus represent the prerequisite for response to inhibition with the multi-targeting anti-angiogenic small molecule inhibitor PTK787.